PLoS ONE (Apr 2011)

A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus.

  • Byron E E Martina,
  • Petra van den Doel,
  • Penelope Koraka,
  • Geert van Amerongen,
  • Gunther Spohn,
  • Bart L Haagmans,
  • Lisette B V Provacia,
  • Albert D M E Osterhaus,
  • Guus F Rimmelzwaan

DOI
https://doi.org/10.1371/journal.pone.0018995
Journal volume & issue
Vol. 6, no. 4
p. e18995

Abstract

Read online

West Nile virus (WNV) continues to circulate in the USA and forms a threat to the rest of the Western hemisphere. Since methods for the treatment of WNV infections are not available, there is a need for the development of safe and effective vaccines. Here, we describe the construction of a recombinant influenza virus expressing domain III of the WNV glycoprotein E (Flu-NA-DIII) and its evaluation as a WNV vaccine candidate in a mouse model. FLU-NA-DIII-vaccinated mice were protected from severe body weight loss and mortality caused by WNV infection, whereas control mice succumbed to the infection. In addition, it was shown that one subcutaneous immunization with 10(5) TCID(50) Flu-NA-DIII provided 100% protection against challenge. Adoptive transfer experiments demonstrated that protection was mediated by antibodies and CD4+T cells. Furthermore, mice vaccinated with FLU-NA-DIII developed protective influenza virus-specific antibody titers. It was concluded that this vector system might be an attractive platform for the development of bivalent WNV-influenza vaccines.